cavidi产品代理
cavidi产品代理
1984 年，来自乌普萨拉大学的两位坚定的病毒学家创立了 Cavidi，旨在让全球更容易进行疾病诊断和监测。
他们的工作始于寻找新的 HIV 生物标志物。这导致了世界上第一个病毒载量监测试剂盒，无需费用、专业知识或设备即可提供 PCR 的准确性。
在逆境中发现
面对 2020 年的 COVID-19 大流行，我们的病毒学家认为需要一种易于部署但高度准确的诊断测试。这项工作导致发现了 BOLD（结合寡核苷酸阶梯检测）——一种新型免疫测定信号增强剂，可用于将几乎任何类型的免疫测定的灵敏度提高多达 100 倍。品牌为 Exazym®，它已成功在 SARS-CoV-2 病毒上进行试验，现在正在对许多具有挑战性的生物标志物进行测试。
想象
一个所有人都可以平等获得优质医疗保健的世界。
使命
确保全球所有人都能平等获得基本的诊断和监测测试。
目标
使重要的研究、诊断和监测测试能够在任何实验室的任何地方运行。
How we started
In 1984 two determined virologists from Uppsala University founded Cavidi to make disease diagnostics and monitoring more accessible globally.
Their work began with the search for novel biomarkers for HIV. This led to the world’s first viral load monitoring kit that provided the accuracy of PCR without the expense, expertise, or equipment.
Discovery through adversity
Faced with the COVID-19 pandemic in 2020, our virologists saw the need for an easily deployed yet highly accurate diagnostic test. This work led to the discovery of BOLD (binding oligo ladder detection) — a novel immunoassay signal booster that can be used to increase the sensitivity of virtually any type of immunoassay by a factor of up to 100 times. Branded Exazym®, it was successfully trialed on the SARS-CoV-2 virus and now is being tested on a number of challenging biomarkers.
Vision
A world where all people have equal access to quality healthcare.
Mission
Ensure equal access to essential diagnostic and monitoring tests for all people globally.
Goals
Enable essential research, diagnostic, and monitoring tests to be run in any lab anywhere.
